Autres langues Akebia Therapeutics, Inc.

Actions

AKBA

US00972D1054

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
1,37 ^USD	+5,38%		+3,01%	+10,48%

16/04	Akebia Therapeutics, Inc. et STA Pharmaceutical Hong Kong Limited concluent un deuxième amendement à l'entente d'approvisionnement	CI
28/03	Mise à jour sectorielle : Les actions du secteur des soins de santé progressent avant le marché jeudi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights	02/05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Averoa Seeks EU Approval for Chronic Kidney Disease Drug	23/04
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	16/04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Sector Update: Health Care	28/03
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	28/03
Akebia Shares Rally Premarket After FDA Approves Vafseo	28/03
U.S. FDA approves Akebia's anemia drug	28/03
U.S. FDA approves Akebia's anemia drug	28/03
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis	28/03
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	28/03
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024	15/03
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024	15/03
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M	14/03
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	14/03
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	14/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Akebia Therapeutics, Inc.

Actions

AKBA

US00972D1054

Autres langues

Filtres